Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Annovis Bio (ANVS)
NYSE:ANVS
Holding ANVS?
Track your performance easily
ANVS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$4.53 - $22.49
Previous Close$7.87
Volume129.73K
Average Volume (3M)1.76M
Market Cap
$102.60M
Enterprise Value$98.60M
Total Cash (Recent Filing)$4.00M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta2.18
Next Earnings
Nov 06, 2024EPS Estimate
-$0.51Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.51
Shares Outstanding13,054,018
10 Day Avg. Volume170,072
30 Day Avg. Volume1,764,846
Standard Deviation0.40
R-Squared0.06
Alpha0.04
Financial Highlights & Ratios
Price to Book (P/B)-58.60
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-7.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-3.23
Forecast
1Y Price Target
$36.00Price Target Upside357.43% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Annovis Bio News
Bulls Say, Bears Say
Bulls Say
Clinical DataAnnovis Bio's lead clinical-stage candidate, buntanetap, showed improvement in multiple scores for Parkinson's disease patients.
Financial PositionANVS has sufficient cash to support operations through the planned AD and PD meetings and continuing until the initiation of the two pivotal studies planned.
Intellectual PropertyThe company has filed a new composition of matter patent for a novel crystal form of buntanetap, which offers improved properties such as enhanced solubility and stability, further strengthening its IP portfolio by extending the patent protection by an additional 20 years.
Bears Say
Capital NeedsThe company needs additional capital before the end of the year, which adds financial uncertainty.
Financial PerformanceAnnovis filed its 10-Q reporting 2Q24 results with a net loss of ($5.0M) and ended the period with ~$4.0M in cash on the balance sheet.
Regulatory ApprovalThe total trial missed the primary endpoint, highlighting the need for a longer study to determine true effects.
---
Ownership Overview
22.49% Insiders
3.56% Mutual Funds
14.14% Other Institutional Investors
59.81% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ANVS FAQ
What was Annovis Bio’s price range in the past 12 months?
Annovis Bio lowest stock price was $4.53 and its highest was $22.49 in the past 12 months.
What is Annovis Bio’s market cap?
Currently, no data Available
When is Annovis Bio’s upcoming earnings report date?
Annovis Bio’s upcoming earnings report date is Nov 06, 2024 which is in 60 days.
How were Annovis Bio’s earnings last quarter?
Annovis Bio released its earnings results on Aug 15, 2024. The company reported -$0.44 earnings per share for the quarter, beating the consensus estimate of -$0.628 by $0.188.
Is Annovis Bio overvalued?
According to Wall Street analysts Annovis Bio’s price is currently Undervalued.
Does Annovis Bio pay dividends?
Annovis Bio does not currently pay dividends.
What is Annovis Bio’s EPS estimate?
Annovis Bio’s EPS estimate is -$0.51.
How many shares outstanding does Annovis Bio have?
Annovis Bio has 13,054,018 shares outstanding.
What happened to Annovis Bio’s price movement after its last earnings report?
Annovis Bio reported an EPS of -$0.44 in its last earnings report, beating expectations of -$0.628. Following the earnings report the stock price went up 14.046%.
Which hedge fund is a major shareholder of Annovis Bio?
Currently, no hedge funds are holding shares in ANVS
---
Annovis Bio Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$36.00 (357.43% Upside)
$36.00 (357.43% Upside)
Blogger Sentiment
Bullish
ANVS Sentiment 91%
Sector Average 69%
Sector Average 69%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 4.7%
Last 30 Days ▼ 4.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-31.44%
12-Months-Change
Fundamentals
Return on Equity
-453.01%
Trailing 12-Months
Asset Growth
-77.88%
Trailing 12-Months
Company Description
Annovis Bio
Annovis Bio Inc is a United States based clinical stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neuro degenerative diseases. The pipeline products of the company include ANVS-401, ANVS-405 and ANVS-301.
---
ANVS Stock 12 Month Forecast
Average Price Target
$36.00
▲(357.43% Upside)
Technical Analysis
Bioxcel Therapeutics
―
Alzamend Neuro
―
SELLAS Life Sciences Group
―
Axsome Therapeutics
―
Best Analysts Covering ANVS
1 Year
1 Year Success Rate
4/16 ratings generated profit
1 Year Average Return
-21.92%
reiterated a buy rating 24 days ago
Copying Ram Selvaraju's trades and holding each position for 1 Year would result in 25.00% of your transactions generating a profit, with an average return of -21.92% per trade.
---